Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Temporarily Withdraw Recommendation of Preventive Cervical Cancer Vaccinations
June 18, 2013
- PMDA Building “Database on Unapproved Drugs” to Accelerate Elimination of Drug Lag
June 18, 2013
- Cabinet Approves PM Abe’s Growth Strategy, Regulatory Reform Plan
June 17, 2013
- Council to Discuss Problem of Prolonged Delivery Price Negotiations at Meeting on June 27
June 17, 2013
- Pharmaceutical Affairs Council Approves Revised Draft Plan to Reduce Manufacturing Costs of Blood Products
June 17, 2013
- CSIMC’s Expert Subcommittee on NHI Drug Pricing Affairs to Hold Hearings for Drug Pricing Organization at Next Meeting in July
June 14, 2013
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
- CSIMC Expert Subcommittee: Reps Agree on Need to Redress Price Variations of Generics
June 13, 2013
- Japan’s Target Drug Market Size Revised Up to 12.8 Trillion Yen in 2020: Growth Strategy
June 13, 2013
- Reprocessing of Expired Anti-Influenza Drugs to Be Considered “If Necessary”
June 13, 2013
- Only About 50% of Doctors Aware of ADR Relief System: PMDA
June 12, 2013
- Half of Patients Unaware of New Anticoagulants: Healthy Japan 21 Promotion Forum Survey
June 11, 2013
- Expert Subcommittee to Begin Discussions on Next Year’s NHI Price Revision on June 12
June 11, 2013
- Director Kamada of HPB’s Economic Affairs Division Calls for Cooperation in Promoting Distribution Reform
June 11, 2013
- Bill to Amend PAL Unlikely to Be Enacted in Current Diet Session
June 10, 2013
- MHLW to Establish “PMDA-WEST” in Kansai Region in October
June 10, 2013
- Council Announces “Comprehensive STI Strategy” to Create One Trillion Yen Market for Regenerative Medicine by 2030
June 10, 2013
- Japan Set to Perk Up R&D to Expand Drug Market to 9 Trillion Yen in 2020
June 7, 2013
- MHLW Asks Industry Organization to Take Steps to Ensure Proper COI Management in Response to Diovan Scandal: HPB Director-General at Diet
June 7, 2013
- Abe Vows to Lift Ban on Online OTC Drug Sales; MHLW to Form Panel to Verify Safety
June 6, 2013
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…